Get started
Relay Therapeutics, Inc.Relay Therapeutics, Inc.Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RLAY chart


Full chart

RLAY upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪708.03 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.61 USD
Net income (FY)
‪−341.97 M‬ USD
Revenue (FY)
‪25.55 M‬ USD
Shares float
‪123.36 M‬
Beta (1Y)
2.10

Employees


Employees (FY)
323
Change (1Y)
−4 −1.22%
Revenue / Employee (1Y)
‪79.09 K‬ USD
Net income / Employee (1Y)
‪−1.06 M‬ USD

About Relay Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Sanjiv K. Patel
Website
relaytx.com
Headquarters
Cambridge
Founded
2015
FIGI
BBG00DSS08K9
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RLAY news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RLAY is 4.23 USD — it has decreased by −2.53% in the past 24 hours. Watch Relay Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Relay Therapeutics, Inc. stocks are traded under the ticker RLAY.
RLAY stock has fallen by −11.32% compared to the previous week, the month change is a −8.44% fall, over the last year Relay Therapeutics, Inc. has showed a −60.76% decrease.
We've gathered analysts' opinions on Relay Therapeutics, Inc. future price: according to them, RLAY price has a max estimate of 30.00 USD and a min estimate of 16.00 USD. Watch RLAY chart and read a more detailed Relay Therapeutics, Inc. stock forecast: see what analysts think of Relay Therapeutics, Inc. and suggest that you do with its stocks.
RLAY reached its all-time high on Jan 20, 2021 with the price of 64.37 USD, and its all-time low was 4.11 USD and was reached on Dec 18, 2024. View more price dynamics on RLAY chart.
See other stocks reaching their highest and lowest prices.
RLAY stock is 4.20% volatile and has beta coefficient of 2.10. Track Relay Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Relay Therapeutics, Inc. there?
Today Relay Therapeutics, Inc. has the market capitalization of ‪708.03 M‬, it has decreased by −3.56% over the last week.
Yes, you can track Relay Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Relay Therapeutics, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
RLAY earnings for the last quarter are −0.63 USD per share, whereas the estimation was −0.77 USD resulting in a 18.38% surprise. The estimated earnings for the next quarter are −0.57 USD per share. See more details about Relay Therapeutics, Inc. earnings.
Relay Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪88.89 K‬ USD. In the next quarter, revenue is expected to reach ‪6.76 M‬ USD.
RLAY net income for the last quarter is ‪−88.11 M‬ USD, while the quarter before that showed ‪−92.21 M‬ USD of net income which accounts for 4.45% change. Track more Relay Therapeutics, Inc. financial stats to get the full picture.
No, RLAY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 323.00 employees. See our rating of the largest employees — is Relay Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Relay Therapeutics, Inc. EBITDA is ‪−389.45 M‬ USD, and current EBITDA margin is ‪−1.46 K‬%. See more stats in Relay Therapeutics, Inc. financial statements.
Like other stocks, RLAY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Relay Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Relay Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Relay Therapeutics, Inc. stock shows the strong sell signal. See more of Relay Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.